Bioanalytical Systems (BASI) Earns Media Sentiment Rating of 0.09
Media headlines about Bioanalytical Systems (NASDAQ:BASI) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.987934147692 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Bioanalytical Systems (NASDAQ:BASI) last posted its earnings results on Monday, August 14th. The company reported $0.03 earnings per share (EPS) for the quarter. Bioanalytical Systems had a negative net margin of 5.88% and a negative return on equity of 20.72%. The business had revenue of $5.84 million for the quarter.
COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/01/bioanalytical-systems-basi-earns-media-sentiment-rating-of-0-09.html.
About Bioanalytical Systems
Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.
Receive News & Stock Ratings for Bioanalytical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems Inc. and related stocks with our FREE daily email newsletter.